Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Glargine Insulin

Abigail M. Cunningham  1 , Andrew M. Freeman  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Glargine Insulin

Abigail M. Cunningham et al.
Free Books & Documents

Excerpt

Insulin glargine is a synthetic version of human insulin that is FDA-approved to treat adults and children with type 1 diabetes and adults with type 2 diabetes to improve and maintain glycemic control. Insulin glargine is a long-acting insulin injected once daily and provides a basal insulin level throughout the day. Regimens often combine it with rapid-acting insulin to obtain optimal glycemic control. The insulin should not be used to treat diabetic ketoacidosis, as short-acting insulin is preferred. This activity will cover the indications, mechanism of action, adverse effects, contraindications, monitoring, and toxicity of insulin glargine pertinent for healthcare professionals.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Abigail Cunningham declares no relevant financial relationships with ineligible companies.

Disclosure: Andrew Freeman declares no relevant financial relationships with ineligible companies.

References

    1. Ghosal S, Sinha B, Majumder A, Das AK, Singh AK, Ghoshdastidar B, Maji D, Goyal G, Mukherjee JJ, Gangopadhyay KK, John M, Chatterjee S, Jaggi S, Ray S, Majumdar S, Sharma SK. Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?". J Assoc Physicians India. 2017 Jul;65(7):51-62. - PubMed
    1. Finneran MM, Landon MB. Oral Agents for the Treatment of Gestational Diabetes. Curr Diab Rep. 2018 Sep 28;18(11):119. - PubMed
    1. Alfadhli EM. Gestational diabetes mellitus. Saudi Med J. 2015 Apr;36(4):399-406. - PMC - PubMed
    1. Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014 Jan 01;6(1) - PMC - PubMed
    1. Candido R, Wyne K, Romoli E. A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus. Diabetes Ther. 2018 Jun;9(3):927-949. - PMC - PubMed

Publication types

LinkOut - more resources